List view / Grid view

News

Seattle Genetics and Bristol-Myers Squibb announce clinical collaboration to evaluate combination of Adcetris® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Hematologic Malignancies

12 January 2015 | By Bristol-Myers Squibb Company

Seattle Genetics, Inc. and Bristol-Myers Squibb Company announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in two planned Phase 1/2 clinical trials...

CheckMate -017, a Phase 3 study of Opdivo (Nivolumab) compared to Docetaxel, stopped early

12 January 2015 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC) was stopped early because an assessment conducted by the independent Data Monitoring Committee...

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk

9 January 2015 | By Daiichi Sankyo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism...

Global healthcare consulting market grows to over $6bn

8 January 2015 | By DWP Public Relations

Changing demographics, ever-evolving regulatory schemes, political pressure to cut costs and social pressure to improve care has led to strong growth in consulting to the global healthcare sector...

Ferrer licenses commercialisation rights for Ozenoxacin in Canada to Cipher Pharmaceuticals Inc.

8 January 2015 | By Andrew Lloyd & Associates

Ozenoxacin, a novel bactericidal non-fluorinated quinolone, will complete a second phase III clinical trial in adult and paediatric patients with impetigo in the first quarter of 2015...

Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress

8 January 2015 | By Oxford Global Conferences

Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA...

Celiac disease treatment market to grow more than tenfold to $551 million by 2023, says GlobalData

7 January 2015 | By GlobalData

The celiac disease treatment market value will expand more than tenfold from an estimated $49.6 million in 2013 to $551.1 million by 2023, at an impressive Compound Annual Growth Rate (CAGR) of 27.24%, according to research and consulting firm GlobalData...

Mundipharma receives positive EC decision on Targin® (oxycodone / naloxone) for Restless Legs Syndrome

7 January 2015 | By Mundipharma

Mundipharma announced that Targin® (Targinact®, Targiniq®), a fixed combination of prolonged-release oxycodone/naloxone, has received a positive European Commission decision for a new indication, as a second line symptomatic treatment for patients with severe to very severe idiopathic restless legs syndrome (RLS), after failure of dopaminergic therapy...

Photocure announces end of Phase 2 status achieved for Cevira in U.S.

7 January 2015 | By Photocure

Cevira advances towards Phase 3 for treatment in patients with cervical high grade lesions (HSIL)...

Bristol-Myers Squibb receives accelerated approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration

6 January 2015 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use...

Bristol-Myers Squibb and Calibr sign worldwide agreement focused on new treatment approaches for fibrotic diseases

5 January 2015 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and the California Institute for Biomedical Research (Calibr) announced they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration...

Merck acquires OncoEthix, a privately held oncology company developing novel BET inhibitors for hematological and solid cancers

19 December 2014 | By Merck

Acquisition expands Merck’s oncology portfolio with novel oral BET inhibitor, OTX015...

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer

19 December 2014 | By Roche

Roche announced top-line results of the Phase III MARIANNE study...

Pfizer reports top-line results from a Phase 3 study evaluating pregabalin controlled-release formulation as a treatment for patients with postherpetic neuralgia

19 December 2014 | By Pfizer

Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN).

Lilly’s CYRAMZA(R) (ramucirumab) receives third FDA approval

17 December 2014 | By Eli Lilly and Company

Eli Lilly and Company has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA(R) (ramucirumab)...

Page 520 of 776
<
1
...
515
516
517
518
519
520
521
522
523
524
...
776
>

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Recommended

News